Immunohistochemical characteristics of brain metastases and corresponding primary lung cancer

被引:1
|
作者
Marinova, Dora Marinova [1 ,2 ]
Mekov, Evgeni Vitkov [1 ,2 ]
Dimitrova, Denitsa Gosheva [1 ,2 ]
Titorenkov, Plamen Todorov [3 ]
Mihailov, Miroslav Martinov [1 ,2 ]
Nachev, Sevdalin Slavov [4 ]
Youroukova, Vania Milosheva [1 ,2 ]
Kostadinov, Dimitar Temelkov [1 ,5 ]
Slavova, Yanina Georgieva [1 ,6 ]
机构
[1] Med Univ, Clin Ctr Lung Dis, Sofia, Bulgaria
[2] Univ Hosp Pulm Dis St Sofia, Dept Pneumonol, Sofia, Bulgaria
[3] Sofia Univ, Mil Med Acad, Fac Med, Sofia, Bulgaria
[4] Univ Hosp St Ivan Rilski, Dept Pathol, Sofia, Bulgaria
[5] Univ Hosp Pulm Dis St Sofia, Dept Bronchol, Sofia, Bulgaria
[6] Univ Hosp Pulm Dis St Sofia, Dept Pathol, Sofia, Bulgaria
来源
JOURNAL OF BUON | 2019年 / 24卷 / 04期
关键词
brain metastases; immunohistochemistry; lung cancer; CELL CARCINOMA; SURVIVAL; PATTERN;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To study brain metastases (BM) and their corresponding primary lung cancers (LCs). Methods: Surgically resected BMs and their corresponding primary LCs from 30 patients (25 men, 83%, age 55 +/- 9 years) were studied: 21 adenocarcinomas (ACs), 5 squamous cell carcinomas (SCCs), 4 small cell lung carcinomas (SCLCs). The histological subtype, immunohistochemical expression of TTF1, p63, Ki67 (proliferative activity), CD31, number of intratumoral microvessels, (NIM) and survival were evaluated. Results: There was a different histological structure in 47% of the cases of ACs of the lung in comparison with the corresponding metastasis, but none in SCC and SCLC. TTF-1 was expressed in a greater number of ACs (n=20; 95%), with lower mean expression levels, while the corresponding BM expressed the marker less frequently (n=16; 76%) with higher mean expression values (p=0.011). P63 was expressed in all SCCs (p=0.68). Cytokeratin 7 was expressed equally in all ACs. Ki-67 proliferative index (PI) was higher in SCLC than in AC (p=0.008), in SCLC BM than in AC BM (p<0.001), and in SCLC BM than in SCC BM (p=0.008). The Ki-67 PI in BM was higher than in AC (p=0.003), SCC (p=0.048), but without difference in SCLC (p=0.141). CD31 NIM was higher in AC than in SCLC (p=0.003), in SCC than in SCLC (p=0.009), while no difference between AC and SCC was found (p=0.467). There were no differences between LC/BM in the NIM. Survival after surgery for LC was significantly longer in AC than in SCLC (p=0.017). SCLC histology and Ki67>18% were established as negative prognostic factors after surgery for LC. Such factors were not found after surgery for BM. Conclusion: There are differences between primary LC and corresponding BM - in histology, immunohistochemical expression and proliferative activity, but there are no significant differences in vascularization. SCLC histology and Ki67>8% may represent negative prognostic factors after surgery for LC with BM.
引用
收藏
页码:1626 / 1637
页数:12
相关论文
共 50 条
  • [1] TREATMENT OF BRAIN METASTASES FROM PRIMARY LUNG-CANCER
    RYAN, GF
    BALI, DL
    SMITH, JG
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (02): : 273 - 278
  • [2] Breast metastases from primary lung cancer: a retrospective case series on clinical, ultrasonographic, and immunohistochemical features
    Wang, Bo
    Jiang, Yingy
    Li, Shi Yu
    Niu, Rui Lan
    Blasberg, Justin D.
    Kaifi, Jussuf T.
    Liu, Gang
    Li Wang, Zhi
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (07) : 3226 - 3235
  • [3] Comparison of the molecular profile of brain metastases from colorectal cancer and corresponding primary tumors
    Aprile, Giuseppe
    Casagrande, Mariaelena
    De Maglio, Giovanna
    Fontanella, Caterina
    Rihawi, Karim
    Bonotto, Marta
    Pisa, Federica E.
    Tuniz, Francesco
    Pizzolitto, Stefano
    Fasola, Gianpiero
    FUTURE ONCOLOGY, 2017, 13 (02) : 135 - 144
  • [4] Lung Cancer Brain Metastases
    Goldberg, Sarah B.
    Contessa, Joseph N.
    Omay, Sacit B.
    Chiang, Veronica
    CANCER JOURNAL, 2015, 21 (05) : 398 - 403
  • [5] Results of surgical treatment of primary lung cancer with synchronous brain metastases
    Bella, Mariusz Jan
    Kowalewski, Janusz
    Dancewicz, Maciej
    Blawat, Przemyslaw
    Szczesny, Tomasz Jaroslaw
    Chrzastek, Aleksandra
    Wnuk, Pawel
    KARDIOCHIRURGIA I TORAKOCHIRURGIA POLSKA, 2015, 12 (01): : 14 - 17
  • [6] Primary systemic therapy for patients with brain metastases from lung cancer ineligible for targeted agents
    Carsten Nieder
    Siv G. Aanes
    Ellinor Haukland
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 3109 - 3116
  • [7] Primary systemic therapy for patients with brain metastases from lung cancer ineligible for targeted agents
    Nieder, Carsten
    Aanes, Siv G.
    Haukland, Ellinor
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (11) : 3109 - 3116
  • [8] The treatment of brain metastases in lung cancer
    Monnet, I.
    Rousseau-Bussac, G.
    Jabot, L.
    Chouaid, C.
    ONCOLOGIE, 2016, 18 (06) : 376 - 384
  • [9] Characteristics of long-term survivors of brain metastases from lung cancer
    Niemiec, Milena
    Glogowski, Maciej
    Tyc-Szczepaniak, Dobromira
    Wierzchowski, Marek
    Kepka, Lucyna
    REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2011, 16 (02) : 49 - 53
  • [10] Characteristics of patients with brain metastases from lung cancer in a palliative care center
    Ryuya Yamanaka
    Hatsuyo Koga
    Yousuke Yamamoto
    Shinichi Yamada
    Tomomi Sano
    Tetsushi Fukushige
    Supportive Care in Cancer, 2011, 19 : 467 - 473